Newman, J. E., Paul, R. C., & Chambers, G. M. (2024). Assisted Reproductive Technology in Australia and New Zealand 2022. National Perinatal Epidemiology and Statistics Unit, UNSW Sydney.
Newman JE, Paul RC, Chambers GM. Assisted Reproductive Technology in Australia and New Zealand 2022. National Perinatal Epidemiology and Statistics Unit, UNSW Sydney; 2024.
Newman, J. E., et al. Assisted Reproductive Technology in Australia and New Zealand 2022. National Perinatal Epidemiology and Statistics Unit, UNSW Sydney, 2024.
For EndNote, Zotero or Mendeley:
License
Open-access status not yet checked.
RRM Academy Synopsis
ART Live Birth Rates in Australia and New Zealand Fall With Age
This annual registry report covers 108,913 ART (IVF and related) treatment cycles carried out across Australian and New Zealand clinics in 2022. For fresh embryo transfers, comparing women under 30 to women over 44, live birth rates fell from 43 out of 100 to 3 out of 100.
Key Findings
Australian and New Zealand ART units performed 108,913 treatment cycles in 2022. Compared with 2021, cycle counts dropped 2.1% in Australia and, in New Zealand, by 2.4%.
Per embryo transfer, live births reached 25.9% (fresh) and 32.1% (thawed) in 2022, counting all cycle types. The overall rate rose from 27.3% in 2018 to 29.9%.
Age changed outcomes sharply: per embryo transfer, women under 30 saw a 43.3% (fresh) or 38.1% (thaw) rate of live birth, compared with 3.3% and 14.4% for women over 44.
Tracking 37,810 women from their first ART cycle in 2019-2020, 38.9% had a baby by the end of their first complete cycle, rising to 59.5% by a sixth cycle.
Single embryo transfer rose from 90.6% of cycles in 2018 to 94.2% in 2022, alongside a fall in the multiple birth rate from 3.2% to 2.7%.
Interpretation
This is an annual registry report. The report covers cycles reported by all 91 ART units in Australia and all 7 in New Zealand for 2022, so the figures describe national practice across every unit. Most rates here are counted per cycle or per embryo transfer. One exception tracks 37,810 women for two to four years. The cohort's 78.1% estimate for cumulative success after six cycles rests on one assumption the report cannot test. Women who stopped treatment are assumed to have succeeded at the same rate as those who kept going.
RRM Context
Most ART registries count success per cycle, and each new cycle resets the count. ANZARD is different: it also follows one group of women for several years. That is closer to how restorative reproductive medicine tracks outcomes per couple over time.
Our editorial summary of this paper, not the article's abstract.
Key figures
Treatment activity, 2022
Measure
Value
Source
Total ART treatment cycles performed, 2022
108,913
Summary
ART treatment cycles performed in Australia, 2022
100,039
Summary
ART treatment cycles performed in New Zealand, 2022
8,874
Summary
ART cycles per 1,000 women of reproductive age (15-44 years), Australia, 2022
19
Summary
ART cycles per 1,000 women of reproductive age (15-44 years), New Zealand, 2022
8.4
Summary
Share of fresh and/or thaw cycles using own oocytes or embryos (autologous), 2022
approximately 94% (102,013)
Summary
Number of women undertaking autologous fresh and/or thaw cycles, 2022
53,237
Summary
Autologous cycles that were fresh cycles, 2022
62,741 (61.5%)
Chapter 1
Autologous cycles that were thaw cycles, 2022
39,272 (38.5%)
Chapter 1
Pregnancy and birth outcomes, 2022
Measure
Value
Source
Clinical pregnancy rate per initiated ART cycle, excluding donation, surrogacy commissioning and lab-only cycles, 2022
22.9% (24,315)
Table 1
Live birth rate per initiated ART cycle, excluding donation, surrogacy commissioning and lab-only cycles, 2022
18.2% (19,314)
Table 1
Clinical pregnancy rate per embryo transfer, autologous and recipient fresh and thaw cycles, 2022
37.6%
Summary
Live birth rate per initiated autologous fresh cycle, excluding freeze-all cycles, 2022
14.7%
Summary
Live birth rate per autologous fresh embryo transfer, 2022
25.7%
Summary
Live birth rate per initiated autologous thaw cycle, 2022
31.8%
Summary
Live birth rate per autologous thaw embryo transfer, 2022
32.2%
Summary
Live birth rate per embryo transfer, autologous fresh cycles, women under 30, 2022
43.3%
Summary
Live birth rate per embryo transfer, autologous thaw cycles, women under 30, 2022
38.1%
Summary
Embryo transfer practice, 2022
Measure
Value
Source
Fresh and thaw embryo transfer cycles, autologous and recipient, 2022
64,286
Chapter 3
Single embryo transfer share of fresh and thaw embryo transfer cycles, 2022
94.2%
Chapter 3
Double embryo transfer share of fresh and thaw embryo transfer cycles, 2022
5.8%
Chapter 3
Babies born and multiples, 2022
Measure
Value
Source
Total babies born following ART treatment, 2022
20,058
Summary
Liveborn babies following ART treatment, 2022
19,833
Summary
ART babies born from Australian ART Units, 2022
17,963 (89.6%)
Summary
ART babies born from New Zealand ART Units, 2022
2,095 (10.4%)
Summary
Liveborn babies that were singletons at term with normal birthweight, 2022
81.7% (16,206)
Chapter 1
Multiple birth rate, 2022
2.7%
Chapter 1
Cumulative live birth, women starting their first ART cycle 2019-2020 (followed to end of 2022)
Measure
Value
Source
Number of women starting their first ART ovarian stimulation cycle, Jan 2019 to Dec 2020 cohort
37,810
Summary
Live birth achieved by first complete ART cycle, same cohort
38.9%
Summary
Cumulative live birth achieved by sixth complete ART cycle, same cohort
59.5%
Summary
Five-year trend, 2018 to 2022
Measure
Value
Source
Live birth rate per embryo transfer cycle, 2018 to 2022
27.3% to 29.9%
Summary
Live birth rate per fresh embryo transfer cycle, 2018 to 2022
24.6% to 25.9%
Summary
Live birth rate per thaw embryo transfer cycle, 2018 to 2022
29.3% to 32.1%
Summary
Our summary of the report's published figures, each citing its table, figure or section. The full report is at the publisher's link.
A global reference to national IVF registries (HFEA, RTAC, ANZARD, Q-IVF, CDC, DIR, JSOG, CARTR Plus, REDLARA, ESHRE EIM, ICMART) and the codes of practice that govern fertility clinics. What each measures, and what they miss.